Shire Faces New Adderall Threat

Shire Pharmaceuticals is facing a new generic challenge to its key Adderall XR drug from Israel-based drug concern Teva Pharmaceutical. Teva had applied to manufacture a generic version of the hyperactivity treatment, Shire said in a statement this morning. Analysts said the move was widely expected at some point. Teva is one of the World's largest manufacturers of generic drugs. Adderall XR is one of Shire's most important earners at present and is protected by two patents that expire in 2018.

Yahoo News (http://uk.biz.yahoo.com/050223/214/fd2ui.html)